

## LOBBYING REGISTRATION

Lobbying Disclosure Act of 1995 (Section 4)

Check if this is an Amended Registration

1. Effective Date of Registration Oct 17, 2007

2. House Identification Number 34506

Senate Identification Number 48793-48

### REGISTRANT

3. Registrant Name: ACADEMY OF MANAGED CARE PHARMACY  
Address: 100 NORTH PITT STREET, #400  
City: ALEXANDRIA State: VA Zip: 22314

4. Principal place of business (if different from line 3):

5. Telephone number and contact name:  
7036838416 Contact: WILLIAM HERMELIN  
E-mail(optional): bhermelin@amcp.org

6. General description of registrant's business or activities:  
Professional association representing pharmacists working in managed care

### CLIENT

A Lobbying firm is required to file a separate registration for each client. Organizations employing in-house lobbyists should check the box labeled "Self" and proceed to line 10.

Self

7. Client name:

Address:  
City: State: Zip:

8. Principal place of business (if different from line 7):

9. General description of client's business or activities:  
Professional association representing pharmacists working in managed care

### LOBBYISTS

10. Name of each individual who has acted or is expected to act as a lobbyist for the client identified on line 7. If any person listed in this section has served as a "covered executive branch official" or "covered legislative branch official" within two years of first acting as a lobbyist for the client, state the executive and/or legislative position(s) in which the person served.

Name: ANDEL, MELISSA (JAMES)  
Covered Official Position (if applicable): N/A  
Name: DAY, RYAN  
Covered Official Position (if applicable): N/A  
Name: HERMELIN, WILLIAM (BILL)  
Covered Official Position (if applicable): N/A

### LOBBYING ISSUES

11. General lobbying issue areas. Select all applicable codes listed in instructions and on the reverse side of Form LD-1, page 1:

HCR      MMM      PHA

12. Specific lobbying issues (current and anticipated):

Proposed changes to the Medicare prescription drug benefit; adjustments to Medicaid prescription drug reimbursement rates; FDA issues, including additional monitoring of direct-to-consumer advertisements for prescription drugs and additional agency funding; legislation relating to "follow-on" biologic pharmaceuticals; legislation relating to authorized generic prescription drugs; importation of prescription drugs/counterfeit drugs; funding for comparative effectiveness research; health information technology/e-prescribing

### AFFILIATED ORGANIZATIONS

13. Is there an entity other than the client that contributes more than \$10,000 to the lobbying activities of the registrant in a semi-annual period **and** 13. Is there an entity other than the client that contributes more than \$10,000 to the lobbying activities of the registrant in a semi-annual period in whole or in major part plans, supervises or controls the registrant's lobbying activities?

No, then go to line 14.

Yes, then complete the rest of this section for each entity matching the criteria above, then proceed to line 14.

### FOREIGN ENTITIES

14. Is there any foreign entity that:

- a) holds at least 20% equitable ownership in the client or any organization identified on line 13; **OR**
- b) directly or indirectly, in whole or in major part, plans, supervises, controls, directs, finances or subsidizes activities of the client or any organization identified on line 13; **OR**
- c) is an affiliate of the client or any organization identified on line 13 and has a direct interest in the outcome of the lobbying activity?

No, then sign and date the registration.

Yes, then complete the rest of this section for each entity matching the criteria above, then sign and date the registration.

Signature: ON FILE      Date: Feb 13, 2008

Printed Name and Title: WILLIAM HERMELIN, DIRECTOR OF GOVERNMENT RELATIONS -